Photocarcinogenicity of selected topically applied dermatological drugs: Calcineurin inhibitors, corticosteroids, and vitamin D analogs

Dermatology Reports

Volumn 2, Issue 2, 2010, Pages 32-35

  Lerche, Catharina M ^a   Wulf, Hans Christian ^a  

^a Mental Health Center Glostrup   (Denmark)

Author keywords

Calcineurin inhibitor; Corticosteroid; Pimecrolimus; Tacrolimus; Vitamin D analog

Indexed keywords

CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DIFLORASONE DIACETATE; HYDROCORTISONE; HYDROCORTISONE BUTYRATE; PIMECROLIMUS; SDZ 981; TACROLIMUS; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CANCER RISK; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PHOTOCARCINOGENICITY; PSORIASIS; RADIATION PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN TUMOR; STRUCTURE ACTIVITY RELATION; ULTRAVIOLET RADIATION;

EID: 79952461240     PISSN: 20367392     EISSN: 20367406     Source Type: Journal    
DOI: 10.4081/dr.2010.e13     Document Type: Review

References (60)

1. Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and non-melanoma skin cancer. Adv Exp Med Biol 2008;624:162-78.
2. Epstein JH. Chemicals and photocarcinogenesis. Australas J Dermatol 1977;18:57-61.
3. Forbes PD, Beer JZ, Black HS, et al. Standardized protocols for photocarcinogenesis safety testing. Front Biosci 2003; 8:d848-54.
4. Young AR. Cumulative effects of ultraviolet radiation on the skin: cancer and photoaging. Semin Dermatol 1990;9:25-31.
5. Wooltorton E. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns. CMAJ 2005;172:1179-80.
6. Ring J, Barker J, Behrendt H, et al. Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum. J Eur Acad Dermatol Venereol 2005;19:663-71.
7. Ring J, Möhrenschlager M, Henkel V. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy. Drug Saf 2008;31:185-98.
8. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2007;156:203-21.
9. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ 2005;330:516.
10. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-23.
11. Fonacier L, Spergel J, Charlesworth EN, et al. Report of the topical calcineurin inhibitor task force of the american college of allergy, asthma and immunology and the american academy of allergy, asthma and immunology. J Allergy Clin Immunol 2005;115:1249-53.
12. Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007;16:385-93.
13. Ormerod AD. Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Br J Dermatol 2005; 153:701-5.
14. Stern RS. Topical calcineurin inhibitors labeling: putting the "box" in perspective. Arch Dermatol 2006;142:1233-5.[PubMed]
15. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000;2:1-23.
16. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimusan anti-inflammatory drug targeting the skin. Exp Dermatol 2004;13:721-30.
17. Patel TS, Greer SC, Skinner RB Jr. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. Am J Clin Dermatol 2007;8:189-94.
18. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol 2005;53: S17-S25.
19. Bhatia N. Topical immunomodulation: modes of action with clinical correlation. Dermatol Clin 2007;25:147-55, vi.
20. Dé Tran QH, Guay E, Chartier S, Tousignant J. Tacrolimus in dermatology. J Cutan Med Surg 2001;5:329-35.
21. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002;12:618-22.
22. Billich A, Aschauer H, Aszódi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
23. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
24. Kuschal C, Thoms KM, Mori T, et al. Cyclosporin A, but not everolimus, inhibits DNA repair in human fibroblasts and lymphoblasts. Int J Clin Pharmacol Ther 2009;47:38-40.
25. Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol 2005;125:1020-5.
26. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
27. Forbes PD. Relevance of animal models of photocarcinogenesis to humans. Photochem Photobiol 1996;63:357-62.
28. Sambuco C P, Forbes PD, Davies RE, et al. Photocarcinogenesis: measuring the reproducibility of a biologic response to ultraviolet radiation exposure in mice. Front Biosci 2003;8:a26-33.
29. Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Topical tacrolimus in combination with simulated solar radiation does not enhance photocarcinogenesis in hairless mice. Exp Dermatol 2008;17:57-62.
30. Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation. Exp Dermatol 2009;18:246-51.
31. Niwa Y, Terashima T, Sumi H. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003;149:960-7.
32. Jiang H, Yamamoto S, Nishikawa K, Kato R. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993;14:67-71.
33. Tran C, Lübbe J, Sorg O, et al. Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis. Dermatology 2005;211:341-7.
34. Doelker L, Tran C, Gkomouzas A, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006;15: 342-6.
35. Gambichler T, Schlaffke A, Tomi NS, et al. Tacrolimus ointment neither blocks ultraviolet B nor affects expression of thymine dimers and p53 in human skin. J Dermatol Sci 2008;50:115-22.
36. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127:808-16.
37. Margolis DJ, Hoffstad O, Bilker W. Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults. Dermatology 2007;214:289-95.
38. Schneeweiss S, Doherty M, Zhu S, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. Dermatology 2009;219:7-21.
39. McNeill AM, Koo JY. "Unknown Risks" of non-steroid topical medications for atopic dermatitis. Int J Dermatol 2007;46:656-8.
40. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007;157:861-73.
41. Sørensen HT, Mellemkjaer L, Nielsen GL, et al. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004;96:709-11.
42. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
43. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;27:286-90.
44. Ashworth J, Booker J, Breathnach SM. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol 1988; 118:457-69.
45. Fisher LB, Maibach HI. The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol 1971;103:39-44.
46. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.
47. Lubach D, Bensmann A, Bornemann U. Steroid-induced dermal atrophy. Investigations on discontinuous application. Dermatologica 1989;179:67-72.
48. Morman MR. Possible side effects of topical steroids. Am Fam Physician 1981;23: 171-4.
49. Kligman LH, Crosby MJ. Topical tretinoin enhances corticosteroid-induced inhibition of tumorigenesis in hairless mice previously exposed to solar simulating radiation. Cancer Lett 1996;107:217-22.
50. Lowe NJ, Connor MJ, Breeding J, Chalet M. Inhibition of ultraviolet-B epidermal ornithine decarboxylase induction and skin carcinogenesis in hairless mice by topical indomethacin and triamcinolone acetonide. Cancer Res 1982;42:3941-3.
51. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of topical anti-inflammatory agents against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmunol Photomed 1990;7:153-8.
52. Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Topical hydrocortisone, clobetasol pro-pionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice. Exp Dermatol 2010 Jan 25.
53. Pashko LL, Rovito RJ, Williams JR, et al. Dehydroepiandrosterone (DHEA) and 3 beta-methylandrost-5-en-17-one: inhibitors of 7,12-dimethylbenz [a]anthracene (DMBA)-initiated and 12-O-tetrade-canoylphorbol-13-acetate (TPA)-promoted skin papilloma formation in mice. Carcinogenesis 1984;5:463-6.
54. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007; 370:272-84.
55. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989;125:1647-52.
56. De Haes P, Garmyn M, Verstuyf A, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B 2005;78:141-8.
57. Dixon KM, Deo SS, Wong G, et al. Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs. J Steroid Biochem Mol Biol 2005;97:137-43.
58. Wood AW, Chang RL, Huang MT, et al. 1 alpha, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 1983;116:605-11.
59. Wood AW, Chang RL, Huang MT, et al. Stimulatory effect of 1 alpha, 25-dihydroxyvitamin D3 on the formation of skin tumors in mice treated chronically with 7,12-dimethylbenz[a]anthracene. Biochem Biophys Res Commun 1985;130: 924-31.
60. Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice. Exp Dermatol 2010 [Epub ahead of print].